***Myo*-inositol – A potential prophylaxis against premature onset of labour and preterm birth**

Neha Sharma1, Oliver C. Watkins1, Anne H.Y. Chu2, W. Cutfield3, Keith M. Godfrey4, Hannah E. J. Yong2 and Shiao-Yng Chan1,2,#

1Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

2Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research, Singapore.

3Liggins Institute, University of Auckland, Auckland, New Zealand

4MRC Lifecourse Epidemiology Centre and NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust

#Member of the Experts Group on Inositol in Basic and Clinical Research (EGOI)

**Correspondence:** Associate Professor Chan Shiao-yng

E-mail: obgchan@nus.edu.sg, Phone: +65 67722672, Address: Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, 1E Kent Ridge Road, NUHS Tower Block, Level 12, Singapore 119228

**Short title:** *Myo*-inositol and preterm birth

**Keywords:** *Myo*-inositol, preterm birth, labour-onset, preterm pre-labour rupture of membranes, placenta

**Abstract**

The incidence of preterm birth (PTB), delivery before 37 completed weeks of gestation, is rising in most countries.Several recent small clinical trials of *myo*-inositol supplementation in pregnancy, which were primarily aimed at preventing gestational diabetes, have suggested an effect on reducing the incidence of PTB as a secondary outcome, highlighting the potential role of *myo*-inositol as a preventive agent. However, the underlying molecular mechanisms by which *myo*-inositol might be able to do so remain unknown; these may occur through directly influencing the onset and progress of labour, or by suppressing stimuli that trigger or promote labour. This paper presents hypotheses outlining the potential role of uteroplacental *myo*-inositol in human parturition and explains possible underlying molecular mechanisms by which *myo*-inositol might modulate the uteroplacental environment and inhibit preterm labour-onset. We suggest that a physiological decline in uteroplacental inositol levels to a critical threshold with advancing gestation, in concert with an increasingly pro-inflammatory uteroplacental environment, permits spontaneous membrane rupture and labour-onset. A higher uteroplacental inositol level, potentially promoted by maternal *myo*-inositol supplementation, might affect lipid metabolism, eicosanoid production, and secretion of pro-inflammatory chemocytokines, that overall dampen the pro-labour uteroplacental environment responsible for labour-onset and progress, thus, reducing the risk of PTB.Understanding how and when inositol may act to reduce PTB risk would facilitate the design of future clinical trials of maternal *myo*-inositol supplementation and definitively address the efficacy of *myo*-inositol prophylaxis against PTB.

**Introduction**

Preterm birth (PTB), defined as delivery at less than 37 completed weeks of gestation, is a common pregnancy complication that is on the rise globally, with significant impact on offspring health and socioeconomic burden. The general prevention of spontaneous onset of preterm labour has eluded medical practitioners. Presently interventions used in mainstream obstetric practice include progesterone prophylaxis and insertion of a cervical cerclage (1), which are only indicated in women with a history of previous PTB and a short cervix, who are known to be at high risk of PTB (2). Since the vast majority of women who experience a PTB do not have these risk factors, many spontaneous PTB cases are not being prevented by these measures. Thus, novel prophylactic agents against spontaneous PTB, which are safe and easy to administer to a wider obstetric population, are needed. An example of such a strategy would be the ingestion of supplements or nutraceuticals, of which *myo*-inositol is emerging as a potential candidate. A meta-analysis of several small clinical trials of *myo*-inositol supplementation in pregnancy, which were primarily aimed at the prevention of gestational diabetes (GDM), have suggested possible efficacy in reducing the incidence of PTB as a secondary outcome (3; 4). These results highlight a possible role for *myo*-inositol in influencing the timing of spontaneous labour-onset and the occurrence of PTB. However, the mechanisms by which *myo*-inositol might do so have not been studied to date. This paper presents hypotheses of the potential role of *myo*-inositol in human parturition and explains the possible underlying molecular mechanisms by which *myo*-inositol might modulate the uteroplacental environment to inhibit preterm onset of labour and reduce PTB risk.

**Epidemiology of preterm birth**

Worldwide, PTB complicates between 5-18% of livebirths, with variations across countries, ethnicities, and socioeconomic status; generally higher incidences are observed in developing nations and among Black women (5; 6). The incidence of PTB has been rising globally over the past few decades due to a variety of factors, including increasing assisted reproduction resulting in multiple gestation, rising maternal age, cardiometabolic factors (obesity, diabetes, chronic hypertension, metabolic disease), unhealthy lifestyle, environmental factors (stress, pollution), and malnutrition or micronutrient deficiency. PTB is the leading cause of neonatal and infant deaths worldwide, and is associated with learning disability, visual and hearing impairment and chronic diseases (e.g. hypertension, cardiometabolic disorders) that can persist into adulthood, alongside a reduced life expectancy (7; 8). Therefore, the untimely and premature onset of labour resulting in PTB is a major public health burden (5), with costly short- and long-term health, societal and economic consequences. There is, thus, an urgent need to find effective preventive interventions that can reduce the risk of PTB and allow otherwise uncomplicated pregnancies to continue to term.

PTB can result from spontaneous onset of labour, that accounts for two-thirds of cases (9), with the remainder arising iatrogenically from labour induction or caesarean delivery for medically-indicated conditions such as pre-eclampsia, fetal growth restriction, and other maternal or fetal disorders. Preterm prelabour rupture of membranes (PPROM), defined as the spontaneous rupture of membranes occurring prior to 37 weeks’ gestation and before labour-onset, has been reported to occur in around 3% of all pregnancies and is associated with one-third of all PTBs (10; 11). PPROM is thought to result in disruption of the barrier surrounding the fetus that can result in ascending pathogens causing intrauterine infection, increased inflammation and the triggering of preterm labour (12).

Although a history of previous PPROM and spontaneous PTB are significant risk factors predicting a recurrence of preterm birth in subsequent pregnancies, two-thirds of PTB cases have no such history (13). Hence, alongside the need to find biomarkers that can predict PTB, there is a need for intervention strategies that are suitable and safe for more widespread PTB prophylaxis in women with no history of PTB. Of late, neither a large randomised controlled trial (RCT) of progesterone prophylaxis against spontaneous PTB in women at risk of PTB (OPPTIMUM) (14) nor another RCT of an omega-3 fatty acid supplementation for PTB prophylaxis in the general obstetric population (15) showed any overall beneficial effect in reducing the incidence of PTB compared to the respective control groups. Nonetheless, based on recent clinical trials, *myo*-inositol is emerging as a potential intervention that holds promise in reducing the incidence of PPROM and PTB (3; 16).

***Myo*-inositol supplementation and reduced risk of PTB**

Inositol, a carbocyclic sugar alcohol present in all living cells, is naturally found in plants and enriched in a wide variety of foods including cereals, legumes, nuts, seeds and fruits (17). In humans, inositol can be synthesized endogenously from glucose. The human kidney produces up to 4 grams of inositol daily, while a western diet can provide about 1 gram per day (17). *Myo*-inositol, the most abundant of 9 stereoisomers of inositol, is involved in a wide array of physiologically important roles. Inositol can be incorporated into a wide range of inositol derivatives with important structural and bioactive functions. Lipid-containing inositol derivatives such as phosphatidyl-inositol (PI) are an integral part of lipid cell membranes, where they regulate membrane fluidity, permeability, electro-potential and transmembrane transport. Many inositol derivatives such as inositol phosphates act as intercellular and intracellular signalling molecules and play important roles as second messengers in many hormonal signalling pathways including those of insulin and pituitary-derived trophic hormones (18; 19). Some inositol derivatives such as inositol-phospho-glycans (IPGs) even act as endocrine factors, having effects at distant tissues (20). In the context of pregnancy, *myo*-inositol is postulated to be a critical player in maintaining normal pregnancy physiology since underlying inositol dysregulation is implicated in several pregnancy pathologies such as GDM and pre-eclampsia (20).

Several small open-label clinical trials of inositol supplementation for GDM prevention in metabolically at risk pregnant women have observed trends of a reduction in PTB as a secondary outcome, pointing to the possible role of *myo-*inositol in reducing the incidence of PTB (21; 22; 23; 24). When pooled, a meta-analysis of 5 RCTs (total n=927 women) showed that *myo*-inositol supplementation starting from the end of the first trimester resulted in a significant reduction in the risk of PTB (risk reduction [RR] 0.36 [95%CI 0.17-0.73]; p = 0.005) (3). Another meta-analysis comprising a secondary analysis of just 3 of these RCTs in Italian women at risk of GDM (n=595) showed halving in the incidence of PTB (10/291 [3.4%] vs 23/304 [7.6%]; P=0.03) following *myo*-inositol supplementation (4g/day) (4). However, there are no reported details of their aetiologies, nor any common factors between these PTB cases.

The latest published multicentred international double-blind RCT (NiPPeR; n=585), which was not included in previous meta-analyses, compared a nutritional supplement containing *myo*-inositol, probiotics and multiple micronutrients with a standard micronutrient supplement starting preconception and continued throughout pregnancy, with gestational glycaemia as the primary outcome (16). Although there was no difference in gestational glycaemia between the two arms, the study found that intervention reduced the risk of the main secondary outcome of PTB (adjusted RR 0.43 [95% CI 0.22-0.82]), particularly late preterm ones (34+0 to 36+6 weeks’ gestation) and PTBs associated with PPROM (aRR 0.21 [0.06-0.69]). Intervention also reduced the incidence of PPROM itself (aRR 0.39 [0.16-0.97]) (16). This provides the first clue as to the possible mechanisms by which inositol may reduce PTB, although it is unclear if this effect could also be attributed to the other components of the intervention (25), including Vitamins D (26), B6 (27), B12 (28) and zinc (29).

A meta-analysis of six RCTs reported that Vitamin D supplementation alone could reduce the odds of PTB (relative risk reduction 0.57; 95%CI 0.36-0.91) (30). This is consistent with a later trial that identified and supplemented 800 pregnant women with moderate to severe Vitamin D deficiency (<20 ng/mL) and showed a 40% reduction in the occurrence of PTB (31). It has been postulated that such effects could be mediated through Vitamin D’s role as a steroid hormone with progesterone-like activity (32). Recent gene expression and network analyses studies performed on peripheral blood of women with Vitamin D insufficiency compared to those with Vitamin D sufficiency at 10-18 weeks of gestation, further suggested that Vitamin D deficiency might dysregulate inflammatory and immune response pathways in early pregnancy, thereby contributing to pathobiology of PTB (33). However, evidence for the efficacy of Vitamin B12, B6 and zinc supplementation in reducing PTB is sparse or weak (25). While maternal B12 deficiency is associated with an increased risk of PTB (28), there is no clinical trial evidence of the effect of supplementation on this outcome prior to the NiPPeR study. Similarly, a Cochrane systematic review did not find good quality evidence for a reduction in preterm birth with Vitamin B6 supplementation and more studies are required (27). The most recent Cochrane review (25 RCTs, 18,000 women) suggested little or negligible difference in PTB following antenatal zinc supplementation (34), although an earlier review (16 trials of 7637 women) demonstrated a small but significant 14% reduction in PTB compared with placebo, predominantly in women with low income (35). The contribution of these micronutrients, aside from Vitamin D, to PTB risk reduction is currently uncertain, and *myo*-inositol could have a role in mediating the reduced PTB finding in the NiPPeR trial given that similar results were reported in previous *myo*-inositol trials.

Further evidence supporting a potential role of *myo*-inositol in allowing pregnancies to continue to term comes from observational studies. In the longitudinal mother-offspring cohort study GUSTO (Growing Up in Singapore Towards healthy Outcomes) (36), placental inositol was quantified in naturally-conceived pregnancies; even over the short period covering term gestations from 37 to 42 weeks, placental inositol was significantly associated with gestational age (37) with 0.1 (95% CI 0.03 to 0.17; p=0.009) days’ longer gestation with each standard deviation increase in inositol, adjusting for maternal age, ethnicity, parity, pre-pregnancy BMI, neonatal sex, tobacco smoke exposure, mode of delivery, timing of placental collection after delivery, and gestational glycaemia (2h glucose in mid-gestation oral glucose tolerance test). Thus, it is tempting to speculate that a lower level of placental inositol might be associated with spontaneous onset of labour and that a higher level of placental inositol might prolong gestation.

Given that PTB comprises a highly heterogeneous set of pathologies, it is important to establish the biological plausibility, critical gestational windows of effect and mechanistic pathways by which *myo*-inositol could reduce PTB risk. This will enable targeting intervention to specific at-risk groups, timely commencement of intervention, and the conduct of suitably designed clinical trials that can definitively determine *myo*-inositol’s efficacy in preventing PTB in the coming years.

**Key players in human parturition**

Human labour is a complex, multifaceted physiological event, which requires a combination of mechanical, endocrine, and pro-inflammatory factors to act in concert within the maternal-fetal tissues. Gene ontology and KEGG pathway enrichment analyses have established that preterm labour is indeed associated with immune response activation in several gestational tissues including the amniotic and chorionic membranes that surround the fetus, and maternal decidua (38).

***Eicosanoids and arachidonic acid***

Eicosanoids are central to the onset and progress of labour, contributing to cervical ripening, uterine contractions, and membrane rupture. Eicosanoids are bioactive lipids produced through the oxidation of arachidonic acid (AA) or other long-chained polyunsaturated fatty acids (LC-PUFAs), which are enriched in placental tissue. AA, an omega-6 polyunsaturated fatty acid, is a key precursor of several downstream eicosanoids including prostaglandin, thromboxane, leukotrienes and lipoxins. Eicosanoid synthesis occurs primarily through the release of AA from phospholipids through the activity of the enzyme phospholipase A2 (PLA2) followed by activities of Acyl-CoA synthetase (ACSL, which activates AA) (39) and cyclo-oxygenase-2 (COX-2, which mediates production of downstream eicosanoids mainly prostaglandins and thromboxanes) (40; 41; 42).

***Pro-inflammatory cytokines and NFκB***

Pro-inflammatory cytokines like interleukin (IL) -1β, IL-6 and TNF-α are produced by resident leukocytes, infiltrating neutrophils and macrophages within the utero-placental environment (43; 44; 45; 46), and are among the most important cytokines associated with the spontaneous onset of labour. These pro-inflammatory factors act through the NFκB signalling pathway, which is involved in the positive potentiation of labour. Not only is NFκB a prime mediator of pro-inflammatory factor action, but by itself, NFκB also promotes the production of an enhanced pro-inflammatory repertoire to further promote labour (47). Downstream targets of NFκB include labour-associated genes such as several cytokines, COX enzymes, PLA2 and extracellular matrix remodelling enzymes (48). These pro-inflammatory and pro-labour signals then elicit secretion of more chemocytokines, eicosanoids especially prostaglandins, and matrix metalloproteases (MMPs) within the fetal membranes, myometrium and cervix (49). Creation of such a microenvironment promotes weakening of fetal membranes, ripening of the cervix (partly by MMP-mediated degradation of the collagen matrix) and increased myometrial contractility (partly through changes in calcium flux and smooth muscle actin activity), resulting in rupture of membranes, rhythmic myometrial contractions, and cervical dilatation (49; 50).

***Myo*-inositol threshold – A regulator for onset of labour and PTB risk**

We hypothesize that there is a threshold of uteroplacental inositol below which is “permissive” to labour onset. A physiological decline in uteroplacental inositol content, in concert with a rising pro-inflammatory environment in later gestation, may be permissive to spontaneous membrane rupture and labour-onset. Lower uteroplacental inositol or a premature or accelerated decline in uteroplacental inositol levels might thus increase the risk of PTB, which could be mitigated by maternal inositol supplementation hence reducing the risk of PPROM and PTB (Fig.1).We further hypothesize that the underlying molecular mechanism, whereby higher placental inositol levels can reduce the risk of PPROM and PTB, is through altering placental and amnio-chorionic membrane lipid metabolism, eicosanoid production, and secretion of pro-inflammatory chemocytokines. These inositol-regulated processes together could maintain the tensile strength of fetal membranes, thereby preventing the untimely/premature spontaneous rupture of membranes, as well as suppressing paracrine signals that promote myometrial contractility, to reduce PTB risk.

***Myo-inositol, fatty acids and eicosanoids***

Current data suggest that *myo*-inositol could alter placental lipid metabolism by affecting upstream pathways such as placental fatty acid (FA) uptake from the maternal circulation and FA activation for lipid synthesis (51), and the same may plausibly occur in other uteroplacental tissues. However, the pathways affected appear to be FA-specific with polyunsaturated, mono-unsaturated, and saturated FAs, each responding differently to *myo*-inositol treatment *in vitro* (51). The FA-specificity of different isoforms of enzymes involved in both FA uptake and activation such as Acyl-CoA synthetase (ACSL) may thus allow *myo*-inositol to have multiple separate effects on placental lipid processing depending on FA-type (51). Therefore, *myo*-inositol may selectively modulate the uptake and activation of AA, and the synthesis of AA-lipids, and thus the availability of un-esterified free AA for the generation of eicosanoids. *Myo*-inositol may also affect AA bioavailability by regulating the release of AA from AA-containing phospholipids by enzymes such as PLA2. This notion is plausible given findings in GDM where placentae have a higher level of PLA2 expression (52; 53) and lower placental inositol content (54).

This leads us to postulate that in uncomplicated pregnancy, inositol may supress eicosanoid production by decreasing the bioavailability of un-esterified free AA through decreased AA uptake, increases in AA-lipid synthesis and decreases in AA-lipid catabolism, thus ensuring that until the physiological uteroplacental inositol-decline reaches a critical threshold, the uteroplacental environment is not permissive to labour-onset and uterine quiescence is maintained.

***Myo-inositol, inflammation and matrix metalloproteases***

Research supporting a role of inositol in regulating inflammation has come mainly from the cancer field. For example, in a mouse model of lung cancer, mice fed with a *myo*-inositol-enriched diet showed a significant decrease in pulmonary IL-6 levels (55). It has been reported that inositol hexaphosphate (IP6, phytic acid) may limit inflammatory events in the colonic epithelium and prevent development of colon carcinomas by further modulating the synthesis and secretion of prostaglandins, leukotrienes, and pro-inflammatory cytokines (56). Constitutive activation of NFκB also seems to be inhibited by IP6, especially in the cancer setting. Specifically, *myo*-inositol deficiency in young grass carps leads to increased levels of the p65 subunit of NFκB, suggestive of increased NFκB pathway activation (57). As mentioned earlier, these pro-inflammatory chemocytokines and prostaglandins can also amplify each other in a feed forward loop and further induce production of several MMPs within fetal membranes, cervix and myometrium, which are involved in extracellular matrix degradation thus resulting in membrane rupture, cervical ripening and dilatation (49). There are also reports of IP6 reducing the expression of several MMPs in colon cancer epithelial cells when induced with IL-1β, pointing to a possible role for inositol in also modulating MMPs and subsequent collagen matrix degradation (58). This suggests that inositol might also inhibit MMP activity, which is required for spontaneous fetal membrane rupture.

Such postulated immunomodulatory roles of myo-inositol parallels those reported with another compound, alpha-lipoic acid (ALA), which has also shown effects in reducing the risk of PTB. However, unlike the myo-inositol supplementation trials in pre-symptomatic women, studies of ALA have mainly focused on pregnant women who had already manifested symptoms of threatened preterm labour. ALA has immunomodulating activity through regulation of both pro- and anti-inflammatory pathways (59; 60). An RCT in women after primary tocolysis showed that vaginal ALA treatment significantly increased the production of cervical anti-inflammatory cytokines associated with stabilization of cervical length (61), whilst other studies reported reduction in symptoms of preterm labour such as pelvic pain and uterine contractions (60; 62). It has even been suggested that ALA and myo-inositol may have synergistic effects as demonstrated in the treatment of other conditions such as PCOS in women (63; 64) and diabetic neuropathy in rats (65). It remains to be seen if such synergistic effects could also be applicable to preterm labour.

***Role of the fetoplacental unit in labour onset and progress***

The fetoplacental unit in part dictates the timing of labour-onset through a coordinated series of endocrine and paracrine signalling, and positive potentiation loops, involving the fetal hypothalamic-pituitary-adrenal-placental axis, and the myometrium (66). The role of fetal corticotropin-releasing hormone (CRH) signalling, withdrawal of the suppressive action of progesterone on myometrial contractility and maternal oxytocin secretion in the neuro-myometrial loop, working in concert with eicosanoids and inflammation to influence labour-onset, have all been described over the last few decades.

Now we also postulate that placental and fetal production of inositol might also contribute to determination of timing of labour-onset and labour progress. The contribution of endogenous placental synthesis of *myo*-inositol appears important, with evidence that placental expression of *IMPA1* (enzyme that synthesises *myo*-inositol), is strongly associated with placental inositol content (54). Moreover, fetal tissues, including lungs, kidneys, liver, skeletal muscle and central nervous system are enriched with inositol, with many expressing enzymes capable of inositol synthesis (20). Studies have reported a decline in fetal circulating inositol concentration with advancing gestation, with 125 μM inositol in umbilical cord blood at mid-gestation falling to 86 μM inositol in cord blood at term (67; 68). Furthermore, since the concentrations of inositol both within the fetal circulation (~86 μM) and amniotic fluid (~80 μM) at term are higher than corresponding maternal circulation (~25 μM) (69; 70), it is likely that the fetoplacental unit makes a larger contribution to the general uteroplacental inositol levels than the mother. Factors that regulate fetal and placental inositol synthesis and metabolism are not yet understood, but will be important to establish in order to fully elucidate inositol’s role in human parturition.

***Uteroplacental myo-inositol and parturition***

It remains to be determined whether a decline to a critical threshold of uteroplacental *myo*-inositol acts as a direct trigger for onset of spontaneous labour or acts to release suppression of the triggers of labour, or if the *myo*-inositol decline merely acts to create a general permissive environment that promotes labour onset and progress. It is likely to be through a combination of different pathways with *myo*-inositol working at multiple levels, contributing to determination of timing of labour onset as well as regulating the labour process itself.

We firstly hypothesize that higher placental inositol content could restrain the onset of labour by suppressing placental eicosanoid synthesis and production by reducing AA bioavailability for eicosanoid synthesis or by reducing the activity of enzymes involved in eicosanoid synthesis (Fig. 2). Additionally, inositol could shift AA metabolism towards the production of anti-inflammatory rather than inflammatory eicosanoids, hence regulating the overall balance of pro- and anti- inflammatory factors to suppress the premature onset of labour. Secondly, we hypothesize that inositol might dampen the pro-inflammatory environment by inhibiting the secretion of chemocytokines within the uteroplacental compartment, just as observed in cancer studies, together with inhibiting the activation of the NFκB pathway that is responsible for downstream induction of COX-2 mediated eicosanoid synthesis and other pro-labour entities. As a result, there is an overall suppression of the pro-inflammatory state within the uteroplacental environment (Fig. 2).

We propose that higher uteroplacental inositol levels and diminution in these events could be promoted by maternal inositol supplementation. Although endogenous fetoplacental inositol are postulated to be major contributors to the prevailing level of uteroplacental inositol, we believe that maternal supplementation could still make an appreciable contribution to uteroplacental and amnio-chorionic membrane inositol content. If so, maternal *myo*-inositol supplementation may act to delay the rupture of membranes and onset of labour and reduce PPROM and PTB risk.

To verify these hypotheses in the laboratory setting, uteroplacental tissues and amnio-chorionic membranes levels of *myo*-inositol, both in *ex* *vivo* frozen biopsies (comparing tissues from *myo*-inositol supplemented and unsupplemented women) and *in* *vitro* explant cultures (treated with varying doses of *myo*-inositol), could be quantified and associated with different AA-containing lipids and eicosanoids. This could be coupled with measurements of expression changes in the enzymes and lipids involved in eicosanoid production, levels of pro-inflammatory and anti-inflammatory chemocytokines, and subsequent activation of the NFκB pathway. Furthermore, the combined effect of these *myo*-inositol-associated changes on the overall tensile strength of amnio-chorionic membranes could be measured and the paracrine effects on myometrial contractility examined. Such studies will be crucial in increasing the mechanistic understanding of inositol’s possible role in the labour process and confirm whether maternal *myo*-inositol supplementation acts through these mechanisms to reduce PPROM and PTB.

**Conclusion**

Currently in standard obstetric practice, there are no clinically efficacious interventions that can safely regulate uteroplacental inflammatory processes and lipid/eicosanoid metabolism to inhibit or delay the onset of PTB in the general obstetric population. Thus, identifying such candidates remains a research priority. Multiple studies have reported *myo*-inositol as a safe compound with no apparent side-effects when used up to a dosage of 4g/day throughout pregnancy. Additionally, *myo*-inositol is easy to administer as an oral supplement, with high compliance reported. Nevertheless, further evaluation of potential adverse effects of *myo*-inositol supplementation, in particular on rarer pregnancy outcomes, which present studies are underpowered to assess adequately, needs to be studied in more detail. This will ensure a favourable risk-benefit ratio as well as cost-effectiveness, before any widespread supplementation can be recommended. *Myo*-inositol’s potential use as a mainstream clinical intervention for prophylaxis against PPROM and PTB could have a significant impact should large clinical trials demonstrate efficacy. Uncovering the biological mechanisms and understanding how inositol could play a key role in delaying the spontaneous onset of labour in PTB pathologies will enable us to more precisely target critical time-windows (preconception or during specific gestational periods) and relevant populations for maternal *myo*-inositol supplementation in new RCTs designed specifically to definitively address the clinical efficacy and safety of *myo*-inositol prophylaxis against PPROM and PTB.

**Financial support**

This study is supported by a Clinician Scientist Award awarded to Chan S.Y. from the Singapore National Medical Research Council (NMRC/CSA-INV/0010/2016; MOH-CSAINV19nov-0002), by the National University of Singapore, National University Health System Singapore and the A\*STAR Singapore Institute for Clinical Sciences. KMG is supported by the UK Medical Research Council (MC\_UU\_12011/4), the National Institute for Health Research (NIHR Senior Investigator (NF-SI-0515-10042) and NIHR Southampton Biomedical Research Centre (IS-BRC-1215-20004)), the European Union (Erasmus+ Programme ImpENSA 598488-EPP-1-2018-1-DE-EPPKA2-CBHE-JP) and the British Heart Foundation (RG/15/17/3174),

**Conflict of Interest**

Chan S.Y., Cutfield W. and Godfrey K. M. are part of an academic consortium that has received grants from Société Des Produits Nestlé S.A. and are co-inventors on patent filings by Nestlé S.A. relating to inositols in human health applications. Chan S.Y. has received reimbursement and honoraria into her research funds from Nestlé S.A. for a half-day consultancy and for speaking at a conference. All other authors have no conflict of interest to declare.

**Authorship**

Manuscript was written by Sharma N and Chan S.Y. with content, advice and editing provided by Watkins O.C., Chu A.H.Y., Cutfield W., Godfrey K.M. and Yong H.E.J. Chan S.Y. provided critical revision of the manuscript for intellectual content.

**References**

1. Romero R, Yeo L, Miranda J *et al.* (2013) A blueprint for the prevention of preterm birth: vaginal progesterone in women with a short cervix. *J Perinat Med* **41**, 27-44.

2. National Institute for Health and Care Excellence (2015) Preterm labour and Birth. <https://www.nice.org.uk/guidance/ng25/resources/preterm-labour-and-birth-pdf-1837333576645>. (accessed 8th January 2021)

3. Zhang H, Lv Y, Li Z *et al.* (2019) The efficacy of myo-inositol supplementation to prevent gestational diabetes onset: a meta-analysis of randomized controlled trials. *J Matern Fetal Neonatal Med* **32**, 2249-2255.

4. Santamaria A, Alibrandi A, Di Benedetto A *et al.* (2018) Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. *Am J Obstet Gynecol* **219**, 300.e301-300.e306.

5. Blencowe H, Cousens S, Oestergaard MZ *et al.* (2012) National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. *Lancet* **379**, 2162-2172.

6. Schaaf JM, Liem SM, Mol BW *et al.* (2013) Ethnic and racial disparities in the risk of preterm birth: a systematic review and meta-analysis. *Am J Perinatol* **30**, 433-450.

7. Larroque B, Ancel PY, Marret S *et al.* (2008) Neurodevelopmental disabilities and special care of 5-year-old children born before 33 weeks of gestation (the EPIPAGE study): a longitudinal cohort study. *Lancet* **371**, 813-820.

8. Crump C, Sundquist K, Sundquist J *et al.* (2011) Gestational age at birth and mortality in young adulthood. *Jama* **306**, 1233-1240.

9. Goldenberg RL, Culhane JF, Iams JD *et al.* (2008) Epidemiology and causes of preterm birth. *The lancet* **371**, 75-84.

10. Sae-Lin P, Wanitpongpan P (2019) Incidence and risk factors of preterm premature rupture of membranes in singleton pregnancies at Siriraj Hospital. *J Obstet Gynaecol Res* **45**, 573-577.

11. Dars S, Malik S, Samreen I *et al.* (2014) Maternal morbidity and perinatal outcome in preterm premature rupture of membranes before 37 weeks gestation. *Pak J Med Sci* **30**, 626-629.

12. Romero R, Quintero R, Oyarzun E *et al.* (1988) Intraamniotic infection and the onset of labor in preterm premature rupture of the membranes. *Am J Obstet Gynecol* **159**, 661-666.

13. Noor S, Nazar AF, Bashir R *et al.* (2007) Prevalance of PPROM and its outcome. *J Ayub Med Coll Abbottabad* **19**, 14-17.

14. Norman JE, Marlow N, Messow CM *et al.* (2016) Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial. *Lancet* **387**, 2106-2116.

15. Makrides M, Best K, Yelland L *et al.* (2019) A Randomized Trial of Prenatal n-3 Fatty Acid Supplementation and Preterm Delivery. *N Engl J Med* **381**, 1035-1045.

16. Godfrey KM, Barton SJ, El-Heis S *et al.* (2021) Myo-Inositol, Probiotics, and Micronutrient Supplementation From Preconception for Glycemia in Pregnancy: NiPPeR International Multicenter Double-Blind Randomized Controlled Trial. *Diabetes Care* **44**, 1091-1099.

17. Dinicola S, Minini M, Unfer V *et al.* (2017) Nutritional and Acquired Deficiencies in Inositol Bioavailability. Correlations with Metabolic Disorders. *Int J Mol Sci* **18**, 2187.

18. Croze ML, Soulage CO (2013) Potential role and therapeutic interests of myo-inositol in metabolic diseases. *Biochimie* **95**, 1811-1827.

19. Larner J (2002) D-chiro-inositol--its functional role in insulin action and its deficit in insulin resistance. *Int J Exp Diabetes Res* **3**, 47-60.

20. Watkins OC, Yong HEJ, Sharma N *et al.* (2020) A review of the role of inositols in conditions of insulin dysregulation and in uncomplicated and pathological pregnancy. *Crit Rev Food Sci Nutr*, 1-49.

21. DʼAnna R, Di Benedetto A, Scilipoti A *et al.* (2015) Myo-inositol Supplementation for Prevention of Gestational Diabetes in Obese Pregnant Women: A Randomized Controlled Trial. *Obstet Gynecol* **126**, 310-315.

22. Santamaria A, Di Benedetto A, Petrella E *et al.* (2016) Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. *J Matern Fetal Neonatal Med* **29**, 3234-3237.

23. Matarrelli B, Vitacolonna E, D'Angelo M *et al.* (2013) Effect of dietary myo-inositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: a randomized controlled trial. *J Matern Fetal Neonatal Med* **26**, 967-972.

24. Farren M, Daly N, McKeating A *et al.* (2017) The Prevention of Gestational Diabetes Mellitus With Antenatal Oral Inositol Supplementation: A Randomized Controlled Trial. *Diabetes Care* **40**, 759-763.

25. Samuel TM, Sakwinska O, Makinen K *et al.* (2019) Preterm Birth: A Narrative Review of the Current Evidence on Nutritional and Bioactive Solutions for Risk Reduction. *Nutrients* **11**.

26. Kucukaydin Z, Kurdoglu M, Kurdoglu Z *et al.* (2018) Selected maternal, fetal and placental trace element and heavy metal and maternal vitamin levels in preterm deliveries with or without preterm premature rupture of membranes. *J Obstet Gynaecol Res* **44**, 880-889.

27. Salam RA, Zuberi NF, Bhutta ZA (2015) Pyridoxine (vitamin B6) supplementation during pregnancy or labour for maternal and neonatal outcomes. *Cochrane Database Syst Rev*, Cd000179.

28. Rogne T, Tielemans MJ, Chong MF *et al.* (2017) Associations of Maternal Vitamin B12 Concentration in Pregnancy With the Risks of Preterm Birth and Low Birth Weight: A Systematic Review and Meta-Analysis of Individual Participant Data. *Am J Epidemiol* **185**, 212-223.

29. Chaffee BW, King JC (2012) Effect of zinc supplementation on pregnancy and infant outcomes: a systematic review. *Paediatr Perinat Epidemiol* **26 Suppl 1**, 118-137.

30. Zhou SS, Tao YH, Huang K *et al.* (2017) Vitamin D and risk of preterm birth: Up-to-date meta-analysis of randomized controlled trials and observational studies. *J Obstet Gynaecol Res* **43**, 247-256.

31. Rostami M, Tehrani FR, Simbar M *et al.* (2018) Effectiveness of Prenatal Vitamin D Deficiency Screening and Treatment Program: A Stratified Randomized Field Trial. *The Journal of Clinical Endocrinology & Metabolism* **103**, 2936-2948.

32. Monastra G, De Grazia S, De Luca L *et al.* (2018) Vitamin D: a steroid hormone with progesterone-like activity. *Eur Rev Med Pharmacol Sci* **22**, 2502-2512.

33. Yadama AP, Mirzakhani H, McElrath TF *et al.* (2020) Transcriptome analysis of early pregnancy vitamin D status and spontaneous preterm birth. *PLoS One* **15**, e0227193.

34. Carducci B, Keats EC, Bhutta ZA (2021) Zinc supplementation for improving pregnancy and infant outcome. *Cochrane Database Syst Rev* **3**, Cd000230.

35. Ota E, Mori R, Middleton P *et al.* (2015) Zinc supplementation for improving pregnancy and infant outcome. *Cochrane Database Syst Rev* **2015**, Cd000230.

36. Soh SE, Tint MT, Gluckman PD *et al.* (2014) Cohort profile: Growing Up in Singapore Towards healthy Outcomes (GUSTO) birth cohort study. *Int J Epidemiol* **43**, 1401-1409.

37. Chu AHY, Tint MT, Chang HF *et al.* (2020) High placental inositol content associated with suppressed pro-adipogenic effects of maternal glycaemia in offspring: the GUSTO cohort. *International Journal of Obesity*.

38. Pereyra S, Sosa C, Bertoni B *et al.* (2019) Transcriptomic analysis of fetal membranes reveals pathways involved in preterm birth. *BMC Med Genomics* **12**, 53-53.

39. Kuwata H, Hara S (2019) Role of acyl-CoA synthetase ACSL4 in arachidonic acid metabolism. *Prostaglandins & other lipid mediators* **144**, 106363.

40. Smith WL, Urade Y, Jakobsson P-J (2011) Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. *Chemical reviews* **111**, 5821-5865.

41. Hoxha M (2018) A systematic review on the role of eicosanoid pathways in rheumatoid arthritis. *Adv Med Sci* **63**, 22-29.

42. Sykes L, MacIntyre DA, Teoh TG *et al.* (2014) Anti-inflammatory prostaglandins for the prevention of preterm labour. *Reproduction* **148**, R29-40.

43. Gotsch F, Gotsch F, Romero R *et al.* (2009) The preterm parturition syndrome and its implications for understanding the biology, risk assessment, diagnosis, treatment and prevention of preterm birth. *J Matern Fetal Neonatal Med* **22 Suppl 2**, 5-23.

44. Challis JR, Lockwood CJ, Myatt L *et al.* (2009) Inflammation and pregnancy. *Reprod Sci* **16**, 206-215.

45. Romero R, Dey SK, Fisher SJ (2014) Preterm labor: one syndrome, many causes. *Science* **345**, 760-765.

46. Gomez-Lopez N, StLouis D, Lehr MA *et al.* (2014) Immune cells in term and preterm labor. *Cell Mol Immunol* **11**, 571-581.

47. Lindström TM, Bennett PR (2005) The role of nuclear factor kappa B in human labour. *Reproduction* **130**, 569-581.

48. Allport VC, Pieber D, Slater DM *et al.* (2001) Human labour is associated with nuclear factor-κB activity which mediates cyclo-oxygenase-2 expression and is involved with the ‘functional progesterone withdrawal’. *Molecular Human Reproduction* **7**, 581-586.

49. Gomez-Lopez N, Laresgoiti-Servitje E, Olson DM *et al.* (2010) The Role of Chemokines in Term and Premature Rupture of the Fetal Membranes: A Review1. *Biol Reprod* **82**, 809-814.

50. Sivarajasingam SP, Imami N, Johnson MR (2016) Myometrial cytokines and their role in the onset of labour. *J Endocrinol* **231**, R101-r119.

51. Watkins OC, Islam MO, Selvam P *et al.* (2019) Myo-inositol alters 13C-labeled fatty acid metabolism in human placental explants. *J Endocrinol*.

52. Varastehpour A, Radaelli T, Minium J *et al.* (2006) Activation of Phospholipase A2 Is Associated with Generation of Placental Lipid Signals and Fetal Obesity. *The Journal of Clinical Endocrinology & Metabolism* **91**, 248-255.

53. Gauster M, Desoye G, Tötsch M *et al.* (2012) The Placenta and Gestational Diabetes Mellitus. *Current Diabetes Reports* **12**, 16-23.

54. Pillai RA, Islam MO, Selvam P *et al.* (2020) Placental Inositol Reduced in Gestational Diabetes as Glucose Alters Inositol Transporters and IMPA1 Enzyme Expression. *The Journal of Clinical Endocrinology & Metabolism*.

55. Unver N, Delgado O, Zeleke K *et al.* (2018) Reduced IL‐6 levels and tumor‐associated phospho‐STAT 3 are associated with reduced tumor development in a mouse model of lung cancer chemoprevention with myo‐inositol. *International journal of cancer* **142**, 1405-1417.

56. Kapral M, Wawszczyk J, Sośnicki S *et al.* (2017) Modulating effect of inositol hexaphosphate on arachidonic acid-dependent pathways in colon cancer cells. *Prostaglandins Other Lipid Mediat* **131**, 41-48.

57. Li S-A, Jiang W-D, Feng L *et al.* (2018) Dietary myo-inositol deficiency decreased intestinal immune function related to NF-κB and TOR signaling in the intestine of young grass carp (Ctenopharyngodon idella). *Fish & shellfish immunology* **76**, 333-346.

58. Kapral M, Wawszczyk J, Jurzak M *et al.* (2012) The effect of inositol hexaphosphate on the expression of selected metalloproteinases and their tissue inhibitors in IL-1β-stimulated colon cancer cells. *Int J Colorectal Dis* **27**, 1419-1428.

59. Monastra G, De Grazia S, Cilaker Micili S *et al.* (2016) Immunomodulatory activities of alpha lipoic acid with a special focus on its efficacy in preventing miscarriage. *Expert Opin Drug Deliv* **13**, 1695-1708.

60. Parente E, Colannino G, Ferrara P (2014) Efficacy of magnesium and alpha lipoic acid supplementation in reducing premature uterine contractions. *Open Journal of Obstetrics and Gynecology* **2014**.

61. Grandi G, Pignatti L, Ferrari F *et al.* (2017) Vaginal alpha-lipoic acid shows an anti-inflammatory effect on the cervix, preventing its shortening after primary tocolysis. A pilot, randomized, placebo-controlled study. *J Matern Fetal Neonatal Med* **30**, 2243-2249.

62. Vitrano G, Mocera G, Guardino M *et al.* (2018) Oral plus vaginal alpha-lipoic acid in women at risk for preterm delivery. *IJMDAT* **1**, 104.

63. Genazzani A, Despini G, Santagni S *et al.* (2014) Effects of a combination of alpha lipoic acid and myo-inositol on insulin dynamics in overweight/obese patients with PCOS. Endocrinol. Metab. Synd. 3, 3.

64. Genazzani AD, Prati A, Marchini F *et al.* (2019) Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both. *Gynecol Endocrinol* **35**, 1088-1093.

65. Kishi Y, Schmelzer JD, Yao JK *et al.* (1999) Alpha-lipoic acid: effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy. *Diabetes* **48**, 2045-2051.

66. Alcántara-Alonso V, Panetta P, de Gortari P *et al.* (2017) Corticotropin-Releasing Hormone As the Homeostatic Rheostat of Feto-Maternal Symbiosis and Developmental Programming In Utero and Neonatal Life. *Frontiers in Endocrinology* **8**.

67. Quirk JG, Jr., Bleasdale JE (1983) myo-Inositol homeostasis in the human fetus. *Obstet Gynecol* **62**, 41-44.

68. Pereira GR, Baker L, Egler J *et al.* (1990) Serum myoinositol concentrations in premature infants fed human milk, formula for infants, and parenteral nutrition. *Am J Clin Nutr* **51**, 589-593.


69. Brusati V, Jóźwik M, Jóźwik M *et al.* (2005) Fetal and Maternal Non-glucose Carbohydrates and Polyols Concentrations in Normal Human Pregnancies at Term. *Pediatric Research* **58**, 700-704.

70. Santamaria A, Corrado F, Baviera G *et al.* (2016) Second trimester amniotic fluid myo-inositol concentrations in women later developing gestational diabetes mellitus or pregnancy-induced hypertension. *J Matern Fetal Neonatal Med* **29**, 2245-2247.

**Figure legends and Figures**

**Fig. 1: Proposed role of uteroplacental inositol in determining gestational age of delivery**.

A suboptimal uteroplacental inositol content coupled with its premature or accelerated decline, in concert with a rising pro-inflammatory uteroplacental environment, is permissive to spontaneous membrane rupture and labour-onset thus increasing the risk of preterm prelabour rupture of membranes (PPROM) and preterm birth (PTB), which we postulate can be mitigated by maternal inositol supplementation (Dark blue ---). Different uteroplacental inositol trajectories relate to gestational timing of labour-onset (Red: preterm; Green: Term; Brown: Post-term)

****

**Fig. 2: Hypothetical mechanism of inositol in inhibiting premature onset of labour and lowering preterm birth risk.** We hypothesize firstly thathigh inositol alters the lipid metabolism within the phospholipid membranes by suppressing the release and activation of AA from membrane phospholipids by inhibiting the enzymes PLA2 and ASCL. Secondly, high inositol levels inhibit the synthesis and secretion of pro-inflammatory chemocytokines, and activation of the NFκB pathway, which further reduces the production of COX-2 mediated eicosanoid synthesis, thereby resulting in an overall suppression of the pro-inflammatory environment responsible for rupture of membranes and onset of labour, and hence, reduce the risk of PPROM and PTB. AA- arachidonic acid, PLA2- Phospholipase A2, ASCL- Acyl-CoA synthetase, COX-2- cyclooxygensae-2.

****